SAR 110894

Drug Profile

SAR 110894

Alternative Names: SAR110894; SAR110894D

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antidementias; Antipsychotics; Mood stabilisers
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 31 Jan 2013 Sanofi completes a phase II trial in Alzheimer's disease in US, Australia, Canada, and EU (NCT01266525)
  • 11 Feb 2011 Phase-II clinical trials in Alzheimer's disease in USA (PO)
  • 29 Apr 2009 Phase-I clinical trials in Alzheimer's disease in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top